Dicot

"We would like to thank everyone who participated and subscribed, thus showing their confidence in Dicot. A subscription rate of 83% is a very good outcome in the current market climate and means that we can continue the development of LIB-01 according to plan. With a strong cash position and with great enthusiasm, we now look forward to the start of Dicot’s clinical phase 1 study, which is scheduled for August", says Elin Trampe, CEO of Dicot.

Background
During the first quarter of 2023, Dicot conducted a rights issue of units, with one unit consisting of four new issued shares, three warrants of series TO4, and three warrants of series TO5. Each warrant of series TO4 entitled the holder to subscribe for one new share in Dicot during the subscription period June 1 to June 15, 2023.

Exercised warrants have been replaced by interim shares awaiting registration at the Swedish Companies Registration Office. The conversion of interim shares into shares is expected to take place during week 27, 2023.

Complete terms of the warrants of series TO4 are available at Dicot´s homepage www.dicot.se.

Number of shares and share capital

Through the exercise of the warrants, the number of shares in Dicot increases by 187,738,286 shares, from 437,409,060 to 625,147,346 shares. The share capital increases by SEK 1,314,168.00 from SEK 3,061,863.42 to SEK 4,376,031.42.

For existing shareholders who have not exercised warrants of series TO4, the dilution amounts to approximately 30 percent.

Advisors

Corpura Fondkommission AB (www.corpura.se) acts as financial advisor and Advokatfirman Lindahl KB as legal adviser to the Company in connection to the exercise of warrants. Hagberg & Aneborn Fondkommission AB acts as issuing agent.

For further information, please contact

Elin Trampe, CEO

Phone: +46 739 80 14 08

E-mail: elin.trampe@dicot.se

About Dicot

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 4,100 shareholders. For more information, please visit www.dicot.se.